The University of Chicago will receive $2,624,000 through a Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2022 to June 30, 2026 to investigate the role of amino acid metabolism in pulmonary fibrosis. Through this award, the University of Chicago aims to advance understanding of medical solutions for pulmonary disorders and translate findings into improved patient...
The University of Chicago was awarded a $2,624,000.00 Project Grant from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to fund the research project "TARGETING TISSUE-RESIDENT ALVEOLAR MACROPHAGE METABOLISM IN ACUTE LUNG INJURY". This four-year grant, running from April 1, 2024 to March 31, 2028, supports cutting-edge biomedical research aimed at improving health outcomes for military service members, veterans, and their families. The research...
This federal Project Grant award of $820,000.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) was provided to the University of Chicago to conduct research on "Determining and Exploiting Metabolic Vulnerabilities of Cancer-Associated Fibroblast Heterogeneity." The research project aims to explore metabolic differences within cancer-associated fibroblasts and leverage those findings to develop new therapeutic approaches. The...
The University of Chicago will receive $1,229,184 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) from July 1, 2022 to June 30, 2025. The funding will support research into microRNA-mediated regulation of prostate cancer biology. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research solutions for battlefield medicine. The University of...
This federal Project Grant award, valued at $1,306,778 and awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research focused on investigating the "Immunologic Drivers of Lineage Bias in TP53-mutant Acute Leukemia" at the University of Chicago. The research aims to transform healthcare for military service members and the broader public through innovative and impactful scientific...
The University of Chicago was awarded a $574,000 Project Grant from the Defense Health Agency to support a research project titled "A HUMAN PLURIPOTENT STEM CELL-BASED APPROACH TO IDENTIFYING THE DRIVERS OF PULMONARY CARCINOID". The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for service members and the public through innovative biomedical research. The project, spanning from September 1, 2023 to...
This federal Project Grant award, valued at $1,312,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund the University of Chicago's project to adapt an inhaled substance use intervention for adolescent and young adult cancer survivors. The project aims to transform healthcare for military service members and the broader public by developing innovative approaches to address substance use challenges faced...
The University of Chicago was awarded a $657,882 Project Grant from the Department of the Army Materiel Command Research Development and Engineering Command (RDECOM) under the Basic Scientific Research program (CFDA 12.431). The grant, which runs from September 30, 2024 to September 29, 2025, will support foundational and applied research across diverse scientific and technical domains critical to national security, such as quantum computing, artificial intelligence, materials science, robotics,...
This federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), provides $3,085,852.00 to the University of Chicago to develop novel claudin-2 channel blockers for the treatment of inflammatory bowel disease. The 4-year project, starting on Jul 1, 2024 and ending on Jun 30, 2028, aims to advance the research and development of new therapeutic approaches for this debilitating condition. As a leading...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,612,104.00 to the University of Chicago to develop and evaluate "senescent tumor cell-loaded dendritic cell vaccines for breast cancer." The award, which runs from February 1, 2025 through January 31, 2028, supports advanced medical research to transform healthcare for military service members and the broader public....